Zika Virus Neutralizing Antibody Responses Elicited by Vaccination or Infection - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neutralizing Antibody Responses to Zika Virus Induced by Vaccination or Natural Infection

  • By

  • Claudia M Galindo

  • Yun Ling

  • Eloi Kpamegan

  • Eduardo J M Nascimento

  • Erick Perez-Guzman

  • Juan P Aguilar Ticona

  • Kai Fern Chan

  • Priscila Castanha

  • Darunee Buddhari

  • Aaron Farmer

  • Stefan Fernandez

  • Whitney R Baldwin

  • Maima Kaiser

  • Jesuina Fernandes

  • Melissa Zahralban-Steele

  • Amanda Brinkman

  • Tim Rindfleisch

  • Kelley J Moss

  • Nadine Rouphael

  • Hana M El Sahly

  • Ernesto T A Marques

  • Albert I Ko

  • Camilo J Acosta

  • December 3, 2025

Share

Objective:

To compare neutralizing antibody (nAb) responses generated by the TAK-426 Zika virus vaccine with those elicited by natural Zika virus infection, highlighting the implications for vaccine efficacy.

Key Findings:
  • Participants with natural ZIKV infection exhibited higher levels of nAbs compared to TAK-426 vaccine recipients at all time points, suggesting a need for vaccine improvement.
  • One month post-dose 2, nAb titers in vaccinated recipients were above the calculated threshold of protection for both flavivirus-naive and flavivirus-primed participants, indicating potential short-term efficacy.
  • The kinetics of nAb responses were similar for both groups, showing a peak, decline, and stabilization pattern, which may inform future vaccine strategies.
Interpretation:

The nAbs induced by the current formulation of TAK-426 may not provide adequate protection against ZIKV infection in endemic regions, indicating a need for further evaluation of booster doses to enhance immunity.

Limitations:
  • The study did not demonstrate vaccine non-inferiority, which is critical for assessing its effectiveness.
  • Challenges in conducting traditional phase 3 efficacy studies due to low transmission rates of ZIKV and potential biases in sample selection.
Conclusion:

The findings suggest that the current phase 1 formulation and dosage of TAK-426 may require further optimization to ensure effective protection against ZIKV, emphasizing the urgency for additional research.

Original Source(s)

Zika Virus Neutralizing Antibody Responses Elicited by Vaccination or Infection

  • by Claudia M Galindo, Yun Ling, Eloi Kpamegan, Eduardo J M Nascimento, Erick Perez-Guzman, Juan P Aguilar Ticona, Kai Fern Chan, Priscila Castanha, Darunee Buddhari, Aaron Farmer, Stefan Fernandez, Whitney R Baldwin, Maima Kaiser, Jesuina Fernandes, Melissa Zahralban-Steele, Amanda Brinkman, Tim Rindfleisch, Kelley J Moss, Nadine Rouphael, Hana M El Sahly, Ernesto T A Marques, Albert I Ko, Camilo J Acosta

  • December 3, 2025

Related Content

Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study

Accountable Action End Points for Evaluating Artificial Intelligence in Digital Public Health

Age-specific hospitalization dynamics during a measles outbreak in Nyanza District, Southern Province, Rwanda, 2026: A survival analysis with implications for clinical management